FGF23 rs863224872: Carrier Status and Tumoral Calcinosis
rs863224872 is an extremely rare missense variant located within the fibroblast growth factor 23 (FGF23) gene on chromosome 12. Because it impairs normal phosphate-regulating hormone function, inheriting two pathogenic FGF23 variants causes familial hyperphosphatemic tumoral calcinosis in an autosomal recessive manner. Carrying a single copy does not typically cause symptoms, making it relevant primarily for carrier status and reproductive genetics.
What each genotype means
Typical risk profile
You have two copies of the standard allele and do not carry this specific pathogenic FGF23 variant. Based on current research, individuals with this genotype are not at an elevated risk for familial hyperphosphatemic tumoral calcinosis linked to this site. This result represents the expected baseline profile found in the general population.
Carried by more than 99.9% of individuals across all major global ancestries.
Tumoral calcinosis carrier
You carry one copy of the pathogenic FGF23 missense variant, which is classified as an autosomal recessive trait. Unaffected carriers typically do not show symptoms of familial hyperphosphatemic tumoral calcinosis, though there is a chance of passing the variant to biological offspring. If you are planning a family, discussing carrier screening with a genetic counselor may provide helpful context.
Extremely rare, found in fewer than 1 in 10,000 individuals globally according to gnomAD data.
Increased tumoral calcinosis risk
You have two copies of this pathogenic variant, which is associated with autosomal recessive familial hyperphosphatemic tumoral calcinosis in scientific literature. Individuals with biallelic mutations in FGF23 may have impaired phosphate regulation leading to abnormal calcified masses. Anyone with this finding should review their genetic test results with a clinical geneticist or endocrinologist.
Exceptionally rare globally, occurring in far fewer than 1 in 1,000,000 individuals.
What Is rs863224872 and Where Is It Located?
The genetic variant rs863224872 represents a rare single nucleotide polymorphism in the FGF23 gene, which is mapped to the short arm of chromosome 12. This specific variant causes a missense alteration, meaning that a single DNA nucleotide change alters the amino acid sequence encoded during protein translation. In the human genome, FGF23 contains three protein-coding exons responsible for producing the intact, bioactive fibroblast growth factor 23 hormone. Changes in this coding region can influence how the resulting polypeptide folds, undergoes post-translational modification, or resists premature cellular breakdown. Cataloged in public repositories such as dbSNP and ClinVar, rs863224872 is documented as a rare, clinically significant alteration. Because it changes the structure of a tightly regulated mineral-handling protein, geneticists track this variant to understand its molecular impact on baseline endocrine function and inherited metabolic disorders.
The Biological Role of the FGF23 Gene
The FGF23 gene provides instructions for creating fibroblast growth factor 23, an essential endocrine hormone predominantly secreted by osteocytes and osteoblasts in bone. Its main physiological job is to maintain mineral balance, specifically systemic phosphate homeostasis and vitamin D metabolism. Circulating intact FGF23 acts on the kidneys by binding to FGF receptors in complex with the co-receptor alpha-Klotho. This signaling pathway suppresses the expression of renal sodium-phosphate cotransporters, such as SLC34A1, prompting the kidneys to excrete excess phosphate into urine rather than reabsorbing it into the bloodstream. Additionally, FGF23 suppresses the active production of 1,25-dihydroxyvitamin D. When working normally, intact FGF23 is regulated through precise enzymatic cleavage into inactive fragments, balancing systemic phosphate retention with steady bone mineralization throughout life.
Research and Association with Tumoral Calcinosis
Loss-of-function variants in FGF23, such as rs863224872, are scientifically associated with hyperphosphatemic familial tumoral calcinosis type 2, an autosomal recessive metabolic disorder. When FGF23 undergoes damaging missense changes, the altered hormone is frequently degraded inside cells or fails to be secreted as an intact molecule. The resulting lack of bioactive FGF23 causes the kidneys to reabsorb excessive amounts of phosphate, leading to markedly high serum phosphate levels. Over time, calcium and phosphate precipitate into ectopic, tumor-like calcified deposits in periarticular soft tissues, skin, and vascular beds, alongside dental and bone abnormalities. Current clinical evidence supporting this disease mechanism is well established in medical genetics, but published literature on this specific variant remains limited to rare affected kindreds and clinical case reports due to its extreme scarcity in the general population.
Population Frequency and Carrier Dynamics
Population genomics repositories, including the Genome Aggregation Database (gnomAD), indicate that rs863224872 is exceptionally rare, with an overall allele frequency far below 0.0001 (less than 1 in 10,000 individuals). Because familial tumoral calcinosis requires biallelic loss of function, individuals with only one copy of the variant are considered unaffected carriers. Heterozygous carriers maintain a functional copy of the FGF23 gene that typically produces sufficient intact hormone to manage renal phosphate filtration and avoid soft tissue calcification. If two asymptomatic carriers have children together, each pregnancy carries an autosomal recessive recurrence risk: a 25% chance of inheriting both altered copies and developing tumoral calcinosis, a 50% chance of being an asymptomatic carrier, and a 25% chance of inheriting two non-variant copies.
Interpreting Results and Clinical Perspective
Discovering an FGF23 variant like rs863224872 on an expanded genetic screen or comprehensive sequencing panel provides educational context regarding carrier status rather than a personal medical diagnosis. Carrying one copy does not imply that an individual has tumoral calcinosis or needs active medical treatment, as healthy carriers generally maintain normal mineral levels. Direct-to-consumer testing cannot substitute for comprehensive clinical evaluation, diagnostic imaging, or targeted biochemical labs such as serum phosphate, calcium, and intact FGF23 measurements. Anyone with unexpected findings, symptoms of ectopic soft tissue swelling, or questions regarding reproductive carrier status should discuss their results with a certified genetic counselor or medical geneticist for appropriate family counseling and clinical interpretation.
How common is this variant?
According to large population databases including gnomAD, rs863224872 has an allele frequency below 0.0001, making it an extremely rare variant across all surveyed ancestral groups.
Frequently asked questions
What does being a carrier of rs863224872 mean?
Being a carrier means you carry one mutated copy of the FGF23 gene alongside one normal copy. Because hyperphosphatemic familial tumoral calcinosis follows an autosomal recessive pattern, carriers usually do not experience symptoms or ectopic calcium-phosphate deposits.
How does FGF23 control phosphate in the body?
FGF23 is a hormone released by bone cells that signals the kidneys to excrete phosphate into the urine. Loss-of-function variants prevent the secretion of functional intact hormone, leading to abnormal phosphate accumulation in the blood.
Can rs863224872 cause rickets?
No, this specific loss-of-function variant is linked to high phosphate and tumoral calcinosis. In contrast, hypophosphatemic rickets occurs when gain-of-function variants block FGF23 cleavage, causing excessive phosphate wasting and low blood phosphate.
What steps should I take if I test positive as a carrier?
A carrier result is primarily meaningful for family planning and reproductive genetics. You should consult a genetic counselor or qualified healthcare provider who can evaluate family history, clarify inheritance probabilities, and determine whether partner carrier screening is recommended.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs863224872?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29